Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia
Odd Erik Johansen1, Pål Johan Vanberg1, Bente Kvarv Kilhovd2, Anders Palmstrøm Jørgensen1
1Medical Department, Asker and Baerum Hospital, RUD, Norway; 2Department of Endocrinology, Aker University Hospital, OSLO, Norway
Background: The insulin analogs, glargine and detemir, are associated with reduced hypoglycemia incidence compared with NPH insulin. We assessed the impact of changing basal insulin from NPH to glargine or detemir in patients with type 1 diabetes mellitus who experienced severe hypoglycemia.
Material and methods: A retrospective chart review was conducted that included 73 (31 female) patients (mean age 48 years, diabetes duration 19 years) treated for 12 to 24 months with insulin glargine (n = 43) or detemir (n = 30).
Results: There were no patients who withdrew from treatment due to side effects. The mean treatment duration in both groups was 18 months. Changing from NPH insulin was associated with a −0.3% (p = 0.036) reduction in HbA1c for glargine (baseline 8.8%) and −0.4% (p = 0.040) for detemir (baseline 8.3%) treated patients; insulin dosages increased, respectively by 4.1 (p = 0.045) and 4.3 units (p = 0.004) (mean values). Weight did not increase significantly and the 1-year rate of serious hypoglycemia was 0.25/person/year.
Conclusion: Switching from NPH-insulin to insulin detemir or glargine in type 1 diabetes mellitus patients with previous serious hypoglycemia was associated with a reduction in HbA1c. However, severe hypoglycemia was not completely eliminated, and few patients reached internationally accepted glycemic treatment goals.
Literature search: We searched Medline, PubMed (with key search terms type 1 diabetes, NPH insulin, detemir, glargine and serious hypoglycemia), reference lists and databases of ongoing and completed trials (through July 2008) provided from the manufacturers of the drugs to identify relevant literature.
Keywords: type 1 diabetes mellitus, insulin, observational study, HbA1c, efficacy
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]
Other article by this author:
Effects of telmisartan on office and 24-hour ambulatory blood pressure: an observational study in hypertensive patients managed in primary care
Frederic Kontny, Terje Risanger, Arne Bye, et al
Published Date: 15 January 2010
Readers of this article also read:
Boudreau JD, Somerville MA
Published Date: 11 September 2014
Fabrication of nanoadjuvant with poly-ɛ-caprolactone (PCL) for developing a single-shot vaccine providing prolonged immunity [Corrigendum]
Prashant CK, Bhat M, Srivastava SK, Saxena A, Kumar M, Singh A, Samim M, Ahmad FJ, Dinda AK
Published Date: 21 August 2014
Assessment of antitumor activity and acute peripheral neuropathy of 1,2-diaminocyclohexane platinum (II)-incorporating micelles (NC-4016)
Ueno T, Endo K, Hori K, Ozaki N, Tsuji A, Kondo S, Wakisaka N, Murono S, Kataoka K, Kato Y, Yoshizaki T
Published Date: 19 June 2014
A double-blind, randomized trial, including frequent patient–physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study
Hassanein M, Abdallah K, Schweizer A
Published Date: 28 May 2014
Comorbidity and survival of Danish ovarian cancer patients from 2000–2011: a population-based cohort study
Grann AF, Thomsen RW, Jacobsen JB, Nørgaard M, Blaakaer J, Søgaard M
Published Date: 1 November 2013
Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis
Karabis A, Lindner L, Mocarski M, Huisman E, Greening A
Published Date: 9 September 2013
Shahar E, Shahar DJ
Published Date: 9 March 2013
Sørensen HT, Friborg S, Rungby J, Christiansen JS, Vaag A, Beck-Nielsen H
Published Date: 20 December 2012
Filippo Marzot, Vittorio Pengo
Published Date: 6 April 2009
Diabetes mellitus: a prothrombotic state. Implications for outcomes after coronary revascularization
Clarissa Cola, Salvatore Brugaletta, Victoria Martín Yuste, Bieito Campos, Dominick J Angiolillo, Manel Sabaté
Published Date: 11 January 2009